TY - JOUR
T1 - Home Monitoring of Age-Related Macular Degeneration
T2 - Utility of the ForeseeHome Device for Detection of Neovascularization
AU - Yu, Hannah J.
AU - Kiernan, Daniel F.
AU - Eichenbaum, David
AU - Sheth, Veeral S.
AU - Wykoff, Charles C.
N1 - Funding Information:
Disclosure(s): All authors have completed and submitted the ICMJE disclosures form. The author(s) have made the following disclosure(s): D.F.K.: Consultant - Adverum, Alimera Sciences, Allergan, BVI, EyePoint, Genentech, Mallinckrodt, Notal Vision, Novartis, Physician Recommended Neutriceuticals, Regeneron; Financial support - Adverum, Alimera Sciences, Allergan, EyePoint, Graybug Pharmaceuticals; Lecturer - Alimera Sciences, Allergan, EyePoint, Genentech, Mallinckrodt, Notal Vision, Physician Recommended Neutriceuticals, Regeneron, Spark Therapeutics, D.E.: Consultant - Allergan, Clearside, Dutch Ophthalmic, Eyepoint, Genentech, Gyroscope, Kodiak, NGM, Notal Vision, Novartis, Recens Medical, Regeneron; Financial support - Allergan, Chengdu Kanghong, Clearside, Genentech, Gyroscope, Kodiak, Mylan, Novartis, Opthea, Opthotech; Lecturer - Allergan, Dutch Ophthalmic, Genentech, Notal Vision, Novartis; Equity owner - Boston Image Reading Center, Hemera Biopharmaceuticals, Network Eye, US Retina; Founder - Network Eye, V.S.S.: Consultant - Alimera, Eyepoint, Genentech, Notal Vision, Novartis; Financial support - Apellis, Chengdu Kanghong, Graybug, IONIS Pharmaceuticals, Outlook Therapeutics, Regeneron, C.C.W.: Consultant - Acuela, Adverum, Aerpio, Alimera, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside Biomedical, DORC, Eyepoint, Genentech/Roche, Iveric Bio, Kodiak, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio, Santen, Takeda; Financial support - Adverum, Aerpio, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Gemini Therapeutics, Genentech/Roche, Graybug Vision, IONIS Pharmaceuticals, Iveric Bio, Kodiak, Neurotech, Novartis, Opthea, Outlook Therapeutics, Recens Medical, Regeneron, Regenxbio, Santen, Samsung, Xbrane Biopharma Obtained funding: N/A
Publisher Copyright:
© 2020 American Academy of Ophthalmology
PY - 2021/4
Y1 - 2021/4
N2 - PURPOSE: To evaluate the real-world utility of the ForeseeHome monitoring device (Notal Vision, Ltd., Tel Aviv, Israel) for the detection of conversion from intermediate age-related macular degeneration (iAMD) to neovascular AMD (nAMD) and to compare with results published by the Home Monitoring of the Eye (HOME) study.DESIGN: Retrospective analysis of electronic health records.PARTICIPANTS: Eyes prescribed use of the ForeseeHome device across 4 retinal practices in the United States.METHODS: Usage information was collected from the online ForeseeHome portal for all eyes prescribed the device. For a predetermined subset of eyes, additional clinical information was collected through chart review and analyzed for clinical utility.MAIN OUTCOME MEASURES: Frequency and length of use, number of eyes that used the device, number of eyes that established a baseline measurement, number of eyes that converted to nAMD, and number of alerts.RESULTS: Seven hundred seventy-five eyes of 448 patients were prescribed use of the ForeseeHome device. Six hundred forty-nine eyes (83.7%) used the device at least once; among this population, 478 (73.7%) established a baseline measurement. Patients who established a baseline measurement were significantly younger than those who did not (P < 0.001). Among eyes that established a baseline measurement, 126 (26.4%) had an overall inadequate frequency of use (≥2 tests per week), and 250 (52.3%) did not use the device as frequently as instructed by the manufacturer (≥3 tests per week); 24.7% of eyes discontinued use within 1 year. Of the 136 eyes that established a baseline measurement among 211 eyes prescribed the device at 1 clinical site, 52 alerts were recorded; 3 (6.8%) correctly identified conversion to nAMD and 47 (93.2%) represented false-positive alerts.CONCLUSIONS: Compared with the prospective HOME study, the utility of the ForeseeHome device in the current analysis of clinical practice application was limited. A meaningful proportion of eyes never used the device or could not establish a baseline measurement. Overall frequency of use was low, and continuous use of the device decreased over time. A need exists for improvement in home monitoring technology for eyes with iAMD at risk of conversion to nAMD.
AB - PURPOSE: To evaluate the real-world utility of the ForeseeHome monitoring device (Notal Vision, Ltd., Tel Aviv, Israel) for the detection of conversion from intermediate age-related macular degeneration (iAMD) to neovascular AMD (nAMD) and to compare with results published by the Home Monitoring of the Eye (HOME) study.DESIGN: Retrospective analysis of electronic health records.PARTICIPANTS: Eyes prescribed use of the ForeseeHome device across 4 retinal practices in the United States.METHODS: Usage information was collected from the online ForeseeHome portal for all eyes prescribed the device. For a predetermined subset of eyes, additional clinical information was collected through chart review and analyzed for clinical utility.MAIN OUTCOME MEASURES: Frequency and length of use, number of eyes that used the device, number of eyes that established a baseline measurement, number of eyes that converted to nAMD, and number of alerts.RESULTS: Seven hundred seventy-five eyes of 448 patients were prescribed use of the ForeseeHome device. Six hundred forty-nine eyes (83.7%) used the device at least once; among this population, 478 (73.7%) established a baseline measurement. Patients who established a baseline measurement were significantly younger than those who did not (P < 0.001). Among eyes that established a baseline measurement, 126 (26.4%) had an overall inadequate frequency of use (≥2 tests per week), and 250 (52.3%) did not use the device as frequently as instructed by the manufacturer (≥3 tests per week); 24.7% of eyes discontinued use within 1 year. Of the 136 eyes that established a baseline measurement among 211 eyes prescribed the device at 1 clinical site, 52 alerts were recorded; 3 (6.8%) correctly identified conversion to nAMD and 47 (93.2%) represented false-positive alerts.CONCLUSIONS: Compared with the prospective HOME study, the utility of the ForeseeHome device in the current analysis of clinical practice application was limited. A meaningful proportion of eyes never used the device or could not establish a baseline measurement. Overall frequency of use was low, and continuous use of the device decreased over time. A need exists for improvement in home monitoring technology for eyes with iAMD at risk of conversion to nAMD.
KW - Aged
KW - Aged, 80 and over
KW - Choroidal Neovascularization/diagnosis
KW - Equipment Design
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Monitoring, Physiologic/instrumentation
KW - Retrospective Studies
KW - Tomography, Optical Coherence
KW - United States
KW - Visual Acuity
KW - Wet Macular Degeneration/diagnosis
UR - http://www.scopus.com/inward/record.url?scp=85092714642&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092714642&partnerID=8YFLogxK
U2 - 10.1016/j.oret.2020.08.003
DO - 10.1016/j.oret.2020.08.003
M3 - Article
C2 - 32810682
AN - SCOPUS:85092714642
SN - 2468-6530
VL - 5
SP - 348
EP - 356
JO - Ophthalmology Retina
JF - Ophthalmology Retina
IS - 4
ER -